Dyslipemia in diabetics treated with statins. Results of the Dyslipidemia International Study in Spain;Dislipidemia en población diabé tica tratada con estatinas. Resultados del Dyslipidemia International Study en España

Medicina Clinica

Volumn 141, Issue 10, 2013, Pages 430-436

  Millán, Jesús ^a   Alegría, Eduardo ^b   Guijarro, Carlos ^c   Lozano, Jose V ^d   Vitale, Gustavo C ^e   González Timón, Belén ^e   González Juanatey, José R ^f  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d Centro de Salud Nazaret   (Spain)

^e Medical affairs Merck sharp and Dohme ltd   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cardiovascular risk; Diabetes; Dyslipidemia; Dyslipidemia International Study; Hypercholesterolemia

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; DIABETIC PATIENT; DYSLIPIDEMIA; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; SPAIN; AGED; BLOOD; COMORBIDITY; DIABETES MELLITUS; DRINKING BEHAVIOR; DYSIS STUDY; ESTUDIO DYSIS. DISLIPEMIA; FEMALE; HEART MUSCLE ISCHEMIA; HIPERCOLESTEROLEMIA; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RIESGO CARDIOVASCULAR; RISK; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING;

CARDIOVASCULAR RISK; DIABETES; DYSIS STUDY; DYSLIPIDEMIA; ESTUDIO DYSIS. DISLIPEMIA; HIPERCOLESTEROLEMIA; HYPERCHOLESTEROLEMIA; RIESGO CARDIOVASCULAR;

AGED; ALCOHOL DRINKING; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OBESITY; PRIMARY PREVENTION; RISK; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SMOKING; SPAIN; TRIGLYCERIDES;

EID: 84890157068     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2012.09.030     Document Type: Article

References (27)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-421.
2. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32 Suppl 1:S13-61.
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al.; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364:685-96.
4. Cholesterol Treatment Trialists' (CTT) Collaborators. Cholesterol-lowering treatment in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-25.
5. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32 Suppl 1:S1-201.
6. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al.; National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.
7. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414.
8. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, et al.; Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dislypidaemic patient. Diab Vasc Dis Res. 2008;5:319-35.
9. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Dia-betologia. 2001;44 Suppl 2:S14-21.
10. Gitt AK, Drexel H, Feely J, Ferriè res J, Gonzalez-Juanatey JR, Thomsen KK, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012;19:221-30.
11. Leiter LA, Lundman P, da Silva PM, Drexel H, Jünger C, Gitt AK. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med. 2011;28:1343-51.
12. Gonzá lez-Juanatey JR, Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC. Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en Españ a. Estudio DYSIS-Españ a. Rev Esp Cardiol. 2011;64:286-94.
13. International Diabetes Federation. The IDF Worldwide Definition of the Metabolic Syndrome. Brussels. IDF Communications; 2006 [consultado 12 May 2008]. Disponible en: http://www.idf.org/webdata/docs/IDF Meta def final
14. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-62.
15. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73-8.
16. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes. Diabetes Care. 2007;30:479-84.
17. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46:733-49.
18. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care. 2005;28:101-7.
19. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic síndrome. Am J Cardiovasc Drugs. 2005;5:379-87.
20. Grupo de Trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes. Diabetes mellitus y riesgo cardiovascular. Recomen-daciones del grupo de trabajo Diabetes Mellitus y Enfermedad Cardiovascular de la Sociedad Española de Diabetes 2009. Clin Invest Arterioscl. 2010;22:115-21, http://dx.doi.org/10.1016/j.arteri.2010.03.004.
21. Kotseva K, Wood D, de Backer G, de Bacquer D, PyöräläK, Keil U, EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a com-parison of EUROASPIRE I, II and III surveys in eight European countries. Lancet. 2009;373:929-40.
22. Fodor JG, McPherson R, Dafoe WA, Grenville A. Investigation and treatment of hypercholesterolemia and other dyslipidemias in Canadian primary care practice. CVD Prevention. 1998;1:225-30.
23. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al.; Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-83.
24. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37-45.
25. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341:410-8.
26. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Dia-betes Care. 2009;32:493-8.
27. Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, Linz P, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74, http://dx.doi.org/10.1056/ NEJMMoa1001282.